PriceTargets.com logo

Johnson & Johnson - JNJ Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $175.94
  • Forecasted Upside: 14.92%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$153.10 As of 11/20/2024 01:00 AM ET
▲ +0.09 (0.06%)

This chart shows the closing price for JNJ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Johnson & Johnson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNJ

Analyst Price Target is $175.94
▲ +14.92% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $175.94, with a high forecast of $215.00 and a low forecast of $150.00. The average price target represents a 14.92% upside from the last price of $153.10.

This chart shows the closing price for JNJ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 polled investment analysts is to moderate buy stock in Johnson & Johnson. This rating has held steady since September 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Wolfe ResearchInitiated CoverageOutperform$190.00
11/6/2024GuggenheimBoost TargetNeutral ➝ Neutral$156.00 ➝ $162.00
10/16/2024CitigroupBoost TargetBuy ➝ Buy$180.00 ➝ $185.00
10/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
10/16/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$163.00 ➝ $166.00
10/16/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$178.00 ➝ $181.00
10/16/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$169.00 ➝ $175.00
10/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
10/8/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$175.00 ➝ $178.00
9/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/20/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/3/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
7/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
7/30/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
7/23/2024Daiwa AmericaDowngradeStrong-Buy ➝ Hold
7/23/2024Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$160.00 ➝ $150.00
7/19/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$160.00 ➝ $155.00
7/18/2024Sanford C. BernsteinBoost Target$161.00 ➝ $171.00
7/18/2024TD SecuritiesLower Target$195.00 ➝ $185.00
7/18/2024TD CowenLower TargetBuy ➝ Buy$195.00 ➝ $185.00
7/18/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
7/18/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$167.00 ➝ $169.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
6/17/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
6/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$160.00
5/22/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$175.00
5/16/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$175.00
5/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
4/18/2024HSBCUpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024Bank of AmericaLower TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
3/13/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
2/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$181.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
2/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
1/24/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$170.00 ➝ $169.00
1/24/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$181.00
1/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
1/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
1/3/2024Raymond JamesBoost TargetOutperform ➝ Outperform$172.00 ➝ $175.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/13/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$170.00 ➝ $163.00
12/1/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$178.00
12/1/2023UBS GroupUpgradeNeutral ➝ Buy$167.00 ➝ $180.00
11/17/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
10/18/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$174.00 ➝ $171.00
10/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
10/18/2023Raymond JamesLower TargetOutperform ➝ Outperform$179.00 ➝ $172.00
10/12/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$158.00 ➝ $162.00
10/11/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$172.00 ➝ $174.00
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
10/4/2023Royal Bank of CanadaInitiated CoverageOutperform$178.00
10/2/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
9/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$175.00 ➝ $158.00
9/6/2023HSBCInitiated CoverageHold$175.00
9/5/2023Raymond JamesLower TargetOutperform ➝ Outperform$184.00 ➝ $179.00
8/31/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$187.00 ➝ $172.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
8/31/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$195.00 ➝ $186.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
8/4/2023Atlantic SecuritiesBoost TargetNeutral ➝ Neutral$167.00 ➝ $170.00
7/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
7/24/2023BarclaysBoost TargetEqual Weight$171.00 ➝ $175.00
7/24/2023Raymond JamesBoost TargetOutperform$181.00 ➝ $184.00
7/21/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$187.00
7/21/2023JPMorgan Chase & Co.Boost TargetNeutral$175.00 ➝ $180.00
7/21/2023Stifel NicolausBoost Target$165.00 ➝ $175.00
7/21/2023Credit Suisse GroupBoost TargetNeutral$170.00 ➝ $175.00
5/30/2023CitigroupInitiated CoverageBuy$185.00
5/5/2023Credit Suisse GroupBoost Target$168.00 ➝ $170.00
4/19/2023Atlantic SecuritiesLower TargetNeutral$168.00 ➝ $167.00
4/19/2023Morgan StanleyBoost TargetEqual Weight$179.00 ➝ $183.00
4/19/2023Raymond JamesLower TargetOutperform$185.00 ➝ $181.00
4/10/2023Morgan StanleyLower TargetEqual Weight$180.00 ➝ $179.00
3/28/2023UBS GroupInitiated CoverageNeutral$164.00
2/28/2023GuggenheimInitiated CoverageNeutral$161.00
2/6/2023Piper SandlerLower Target$55.00 ➝ $52.00
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$215.00
1/25/2023Atlantic SecuritiesBoost TargetNeutral$160.00 ➝ $168.00
1/25/2023Morgan StanleyBoost TargetEqual Weight$176.00 ➝ $180.00
1/20/2023Leerink PartnersLower TargetOutperform$194.00 ➝ $186.00
12/12/2022CitigroupBoost TargetBuy$198.00 ➝ $205.00
12/6/2022Morgan StanleyLower TargetEqual Weight$178.00 ➝ $176.00
12/1/2022Morgan StanleyBoost Target$170.00 ➝ $178.00
11/17/2022Credit Suisse GroupInitiated CoverageNeutral$170.00
10/19/2022Atlantic SecuritiesLower TargetNeutral$165.00 ➝ $160.00
10/19/2022Raymond JamesLower TargetOutperform$192.00 ➝ $185.00
10/19/2022Morgan StanleyLower TargetEqual Weight$174.00 ➝ $170.00
10/19/2022Sanford C. BernsteinLower Target$194.00 ➝ $190.00
10/17/2022BarclaysInitiated CoverageEqual Weight$175.00
10/14/2022Bank of AmericaLower TargetNeutral$185.00 ➝ $178.00
10/12/2022Morgan StanleyBoost TargetEqual Weight$173.00 ➝ $174.00
10/5/2022CitigroupLower Target$201.00 ➝ $198.00
9/12/2022Morgan StanleyLower TargetEqual Weight$174.00 ➝ $173.00
7/21/2022UBS GroupLower Target$185.00 ➝ $180.00
7/20/2022Leerink PartnersLower Target$200.00 ➝ $194.00
7/20/2022CitigroupLower Target$205.00 ➝ $201.00
7/13/2022Wells Fargo & CompanyBoost TargetOverweight$190.00 ➝ $195.00
7/8/2022Morgan StanleyBoost TargetEqual Weight$173.00 ➝ $174.00
6/22/2022Daiwa Capital MarketsInitiated CoverageOutperform
5/17/2022CitigroupLower Target$210.00 ➝ $205.00
4/20/2022Raymond JamesBoost TargetOutperform$195.00 ➝ $196.00
4/20/2022Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $205.00
4/20/2022CitigroupBoost TargetBuy$203.00 ➝ $210.00
4/14/2022Raymond JamesBoost TargetOutperform$185.00 ➝ $195.00
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$163.00 ➝ $181.00
4/6/2022Morgan StanleyLower TargetEqual Weight$175.00 ➝ $173.00
3/16/2022Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$180.00 ➝ $183.00
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral
1/26/2022Raymond JamesBoost Target$178.00 ➝ $185.00
1/24/2022Morgan StanleyLower TargetEqual Weight$187.00 ➝ $175.00
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$161.00
12/15/2021CitigroupReiterated RatingBuy ➝ Buy$192.00 ➝ $195.00
10/20/2021Raymond JamesLower TargetOutperform$183.00 ➝ $178.00
10/7/2021Wells Fargo & CompanyReiterated RatingBuy
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$187.00
7/29/2021Leerink PartnersReiterated RatingBuy
7/21/2021Leerink PartnersReiterated RatingOutperform
6/7/2021Credit Suisse GroupSet TargetBuy$193.00
6/1/2021Credit Suisse GroupSet TargetBuy$193.00
5/28/2021Morgan StanleyInitiated CoverageOverweight$187.00
1/27/2021JPMorgan Chase & Co.Boost TargetNeutral$157.00 ➝ $175.00
1/27/2021Credit Suisse GroupBoost TargetOutperform$168.00 ➝ $193.00
1/27/2021Raymond JamesBoost TargetOutperform$158.00 ➝ $183.00
1/27/2021CowenBoost TargetOutperform$170.00 ➝ $195.00
1/27/2021Morgan StanleyBoost TargetOverweight$178.00 ➝ $187.00
1/27/2021Leerink PartnersBoost TargetOutperform$180.00 ➝ $200.00
1/27/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$175.00 ➝ $190.00
1/26/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$180.00 ➝ $200.00
12/15/2020Morgan StanleyBoost TargetOverweight$170.00 ➝ $178.00
11/20/2020Raymond JamesReiterated RatingBuy
10/14/2020Credit Suisse GroupBoost TargetPositive ➝ Outperform$163.00 ➝ $168.00
10/14/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$168.00 ➝ $180.00
10/13/2020Credit Suisse GroupSet TargetBuy$163.00
9/4/2020Credit Suisse GroupReiterated RatingBuy
8/19/2020Stifel NicolausDowngradeBuy ➝ Hold
8/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00
7/20/2020Bank of AmericaReiterated RatingBuy
7/20/2020Independent ResearchUpgradeHold ➝ Buy$161.00 ➝ $164.00
7/17/2020Raymond JamesBoost TargetOutperform$157.00 ➝ $158.00
7/17/2020CitigroupBoost TargetBuy$165.00 ➝ $170.00
7/15/2020Leerink PartnersReiterated RatingOutperform
4/29/2020Morgan StanleyBoost TargetOverweight$160.00 ➝ $170.00
4/29/2020BarclaysBoost TargetOverweight$173.00 ➝ $182.00
4/28/2020Cantor FitzgeraldReiterated RatingBuy$168.00
4/28/2020Credit Suisse GroupReiterated RatingBuy$161.00
4/28/2020UBS GroupDowngradeBuy ➝ Neutral$163.00 ➝ $160.00
4/22/2020Wells Fargo & CompanyUpgradeHold
4/22/2020Bank of AmericaUpgradeNeutral ➝ Buy$150.00 ➝ $175.00
4/15/2020Stifel NicolausBoost TargetHold$140.00 ➝ $155.00
4/15/2020Wells Fargo & CompanyBoost TargetOverweight$150.00 ➝ $162.00
4/15/2020CitigroupBoost TargetBuy$150.00 ➝ $165.00
4/15/2020Raymond JamesBoost TargetOutperform$153.00 ➝ $157.00
4/15/2020Credit Suisse GroupBoost TargetOutperform$155.00 ➝ $161.00
4/9/2020Raymond JamesLower TargetOutperform$161.00 ➝ $153.00
4/8/2020Leerink PartnersLower TargetOutperform$172.00 ➝ $160.00
4/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00
4/2/2020Wells Fargo & CompanyLower TargetOverweight$165.00 ➝ $150.00
4/1/2020Stifel NicolausLower TargetHold$155.00 ➝ $140.00
3/27/2020Morgan StanleyLower TargetOverweight$170.00 ➝ $160.00
3/27/2020CitigroupLower TargetBuy$163.00 ➝ $150.00
3/27/2020ArgusReiterated RatingBuy$165.00 ➝ $155.00
3/6/2020Credit Suisse GroupLower TargetOutperform$170.00 ➝ $159.00
3/4/2020CitigroupInitiated CoverageBuy$163.00
2/17/2020Credit Suisse GroupReiterated RatingBuy$170.00
1/27/2020Credit Suisse GroupBoost TargetOutperform$163.00 ➝ $170.00
1/23/2020Cantor FitzgeraldReiterated RatingBuy$168.00
1/23/2020Raymond JamesBoost TargetOutperform$147.00 ➝ $161.00
1/9/2020Wells Fargo & CompanyBoost TargetOverweight$155.00 ➝ $165.00
12/31/2019Credit Suisse GroupReiterated RatingBuy$163.00
12/19/2019BarclaysUpgradeEqual Weight ➝ Overweight$140.00 ➝ $173.00
12/17/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$145.00 ➝ $170.00
11/27/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

1.21 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 90 very positive mentions
  • 72 positive mentions
  • 29 negative mentions
  • 11 very negative mentions
Mentions as of
4/25/2024
  • 72 very positive mentions
  • 42 positive mentions
  • 11 negative mentions
  • 9 very negative mentions
Mentions as of
5/25/2024
  • 63 very positive mentions
  • 29 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
6/24/2024
  • 85 very positive mentions
  • 36 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 53 very positive mentions
  • 52 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
8/23/2024
  • 58 very positive mentions
  • 65 positive mentions
  • 11 negative mentions
  • 3 very negative mentions
Mentions as of
9/22/2024
  • 65 very positive mentions
  • 77 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 152 very positive mentions
  • 65 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 152 very positive mentions
  • 65 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $153.10
Low: $151.81
High: $153.25

50 Day Range

MA: $160.59
Low: $151.86
High: $167.07

52 Week Range

Now: $153.10
Low: $143.13
High: $168.85

Volume

9,060,825 shs

Average Volume

7,028,536 shs

Market Capitalization

$368.59 billion

P/E Ratio

22.16

Dividend Yield

3.22%

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Johnson & Johnson?

The following Wall Street sell-side analysts have issued research reports on Johnson & Johnson in the last twelve months: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Daiwa America, Daiwa Capital Markets, Guggenheim, HSBC Holdings plc, Morgan Stanley, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, StockNews.com, TD Cowen, TD Securities, The Goldman Sachs Group, Inc., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for JNJ.

What is the current price target for Johnson & Johnson?

0 Wall Street analysts have set twelve-month price targets for Johnson & Johnson in the last year. Their average twelve-month price target is $175.94, suggesting a possible upside of 14.9%. Cantor Fitzgerald has the highest price target set, predicting JNJ will reach $215.00 in the next twelve months. Daiwa Capital Markets has the lowest price target set, forecasting a price of $150.00 for Johnson & Johnson in the next year.
View the latest price targets for JNJ.

What is the current consensus analyst rating for Johnson & Johnson?

Johnson & Johnson currently has 7 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JNJ.

What other companies compete with Johnson & Johnson?

Other companies that are similar to Johnson & Johnson include Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer and Bristol-Myers Squibb. Learn More about companies similar to Johnson & Johnson.

How do I contact Johnson & Johnson's investor relations team?

Johnson & Johnson's physical mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company's listed phone number is (732) 524-0400 and its investor relations email address is [email protected]. The official website for Johnson & Johnson is www.jnj.com. Learn More about contacing Johnson & Johnson investor relations.